PURPOSE: To observe the efficacy and safety of Shaoyang Xibi decoction(SYXBD) in patients with knee osteoarthritis(KOA), and to verify that the theory of "Shaoyang dominating bone" in Traditional Chinese Med...PURPOSE: To observe the efficacy and safety of Shaoyang Xibi decoction(SYXBD) in patients with knee osteoarthritis(KOA), and to verify that the theory of "Shaoyang dominating bone" in Traditional Chinese Medicine(TCM) can be applied to KOA treatment.METHODS: Participants were randomly allocated to two groups: SYXBD(treatment group, n = 66)and Meloxicam(control group, n = 66). Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) and 36-Item Short Form Health Survey(SF-36) were used to assess efficacy before the treatment and 8 weeks after the treatment.RESULTS: Baseline data before the treatment between the two groups were similar. The WOMAC scores significantly decreased and the SF-36 scores significantly increased after 8-week treatment in both groups compared with before the treatment(P < 0.05). SYXBD significantly decreased pain scores(P < 0.001), physical function scores(P <0.001) and the total scores(P < 0.001) in WOMAC compared to Meloxicam. SYXBD significantly improved physical function(P = 0.021), bodily pain(P = 0.002) and general health(P = 0.014), with no significant difference in role emotional(P = 0.053),role physical(P = 0.517), vitality(P = 0.241), social function(P = 0.712) and mental health(P = 0.800)in SF-36 compared to Meloxicam. No adverse events were reported in the treatment group while13 adverse events happened in the control group during the study.CONCLUSION: SYXBD, prepared based on the theory of "Shaoyang dominating bone", has a better curative efficay and safety in patients with KOA compared with Meloxicam. The TCM theory of "Shaoyang dominating bone" may be useful in KOA treatment.展开更多
目的:探讨芪防膝痹颗粒对大鼠膝骨关节炎(KOA)疼痛的影响。方法:选取16周龄SD雌性大鼠40只,分为对照组、模型组、塞来昔布和芪防膝痹颗粒组,每组10只。除对照组外其余行前交叉韧带切除建立KOA,术后分别给予0.9%氯化钠溶液、塞来昔布和...目的:探讨芪防膝痹颗粒对大鼠膝骨关节炎(KOA)疼痛的影响。方法:选取16周龄SD雌性大鼠40只,分为对照组、模型组、塞来昔布和芪防膝痹颗粒组,每组10只。除对照组外其余行前交叉韧带切除建立KOA,术后分别给予0.9%氯化钠溶液、塞来昔布和芪防膝痹颗粒灌胃,8周后取材。Electric Von Frey疼痛仪于术前及术后每周测1次疼痛阈值,Micro-CT扫描后行HE、番红-快绿染色观察滑膜及软骨的改变,免疫组织化学观察IL-1β、TNF-α、VEGF的表达,ELISA测血清IL-6水平。结果:与模型组比较,芪防膝痹颗粒组KOA疼痛阈值显著升高(P<0.05),滑膜炎症和软骨破坏也明显减轻,VEGF在软骨边缘、滑膜以及IL-1β、TNF-α在软骨中表达均降低(P<0.05)。结论:芪防膝痹颗粒可以减轻KOA疼痛和延缓软骨退变,可能与减少滑膜中VEGF表达有关。展开更多
基金Supported by Natural Science Foundation for Youths of Jiangsu Province,China(No.BK20151007)Postgraduate Research&Practice Innovation Program of Jiangsu Province(No.SJLX16_0383)Jiangsu Province Advantage Disciplines Foundation for School of Nursing of Nanjing University of Chinese Medicine(decree No.37 issued by People's Government of Jiangsu Province Office in 2014)
文摘PURPOSE: To observe the efficacy and safety of Shaoyang Xibi decoction(SYXBD) in patients with knee osteoarthritis(KOA), and to verify that the theory of "Shaoyang dominating bone" in Traditional Chinese Medicine(TCM) can be applied to KOA treatment.METHODS: Participants were randomly allocated to two groups: SYXBD(treatment group, n = 66)and Meloxicam(control group, n = 66). Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) and 36-Item Short Form Health Survey(SF-36) were used to assess efficacy before the treatment and 8 weeks after the treatment.RESULTS: Baseline data before the treatment between the two groups were similar. The WOMAC scores significantly decreased and the SF-36 scores significantly increased after 8-week treatment in both groups compared with before the treatment(P < 0.05). SYXBD significantly decreased pain scores(P < 0.001), physical function scores(P <0.001) and the total scores(P < 0.001) in WOMAC compared to Meloxicam. SYXBD significantly improved physical function(P = 0.021), bodily pain(P = 0.002) and general health(P = 0.014), with no significant difference in role emotional(P = 0.053),role physical(P = 0.517), vitality(P = 0.241), social function(P = 0.712) and mental health(P = 0.800)in SF-36 compared to Meloxicam. No adverse events were reported in the treatment group while13 adverse events happened in the control group during the study.CONCLUSION: SYXBD, prepared based on the theory of "Shaoyang dominating bone", has a better curative efficay and safety in patients with KOA compared with Meloxicam. The TCM theory of "Shaoyang dominating bone" may be useful in KOA treatment.
文摘目的:探讨芪防膝痹颗粒对大鼠膝骨关节炎(KOA)疼痛的影响。方法:选取16周龄SD雌性大鼠40只,分为对照组、模型组、塞来昔布和芪防膝痹颗粒组,每组10只。除对照组外其余行前交叉韧带切除建立KOA,术后分别给予0.9%氯化钠溶液、塞来昔布和芪防膝痹颗粒灌胃,8周后取材。Electric Von Frey疼痛仪于术前及术后每周测1次疼痛阈值,Micro-CT扫描后行HE、番红-快绿染色观察滑膜及软骨的改变,免疫组织化学观察IL-1β、TNF-α、VEGF的表达,ELISA测血清IL-6水平。结果:与模型组比较,芪防膝痹颗粒组KOA疼痛阈值显著升高(P<0.05),滑膜炎症和软骨破坏也明显减轻,VEGF在软骨边缘、滑膜以及IL-1β、TNF-α在软骨中表达均降低(P<0.05)。结论:芪防膝痹颗粒可以减轻KOA疼痛和延缓软骨退变,可能与减少滑膜中VEGF表达有关。
